The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Evan, G. I, Christophorou, M. A, Ringshausen, I, Finch, A. J, Swigart, L. Brown
Published in Nature (14.09.2006)
Published in Nature (14.09.2006)
Get full text
Journal Article
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Huppert, L A, Wolf, D, Yau, C, Brown-Swigart, L, Hirst, G L, Isaacs, C, Pusztai, L, Pohlmann, P R, DeMichele, A, Shatsky, R, Yee, D, Thomas, A, Nanda, R, Perlmutter, J, Heditsian, D, Hylton, N, Symmans, F, Veer, L J van 't, Esserman, L, Rugo, H S
Published in Annals of oncology (28.10.2024)
Published in Annals of oncology (28.10.2024)
Get full text
Journal Article
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Du, L., Yau, C., Brown-Swigart, L., Gould, R., Krings, G., Hirst, G.L., Bedrosian, I., Layman, R.M., Carter, J.M., Klein, M., Venters, S., Shad, S., van der Noordaa, M., Chien, A.J., Haddad, T., Isaacs, C., Pusztai, L., Albain, K., Nanda, R., Tripathy, D., Liu, M.C., Boughey, J., Schwab, R., Hylton, N., DeMichele, A., Perlmutter, J., Yee, D., Berry, D., van't Veer, L., Valero, V., Esserman, L.J., Symmans, W.F.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis
Shchors, K, Nozawa, H, Xu, J, Rostker, F, Swigart-Brown, L, Evan, G, Hanahan, D
Published in Oncogene (24.01.2013)
Published in Oncogene (24.01.2013)
Get full text
Journal Article
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Magbanua, M.J.M., Swigart, L.B., Wu, H.-T., Hirst, G.L., Yau, C., Wolf, D.M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., Delson, A.L., DeMichele, A., Liu, M.C., Chien, A.J., Tripathy, D., Asare, S., Lin, C.-H.J., Billings, P., Aleshin, A., Sethi, H., Louie, M., Zimmermann, B., Esserman, L.J., van ‘t Veer, L.J.
Published in Annals of oncology (01.02.2021)
Published in Annals of oncology (01.02.2021)
Get full text
Journal Article
355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
DeMichele, A., Price, E., Venters, S., Li, W., Wolf, D., Gibbs, J., Brown-Swigart, L., Klein, M., Onishi, N., Yau, C., Yee, D., Isaacs, C., Perlmutter, J., Rugo, H.S., Veer, L.J. Van't, Boughey, J., Symmans, F., Hylton, N., Esserman, L.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
314P The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients
Magbanua, M., Rivero-Hinojosa, S., Sayaman, R., Tin, T., Kalashnikova, E., Wolf, D., Brown-Swigart, L., Hirst, G., Yau, C., Isaacs, C., Shatsky, R.A., Delson, A., Palsuledesai, C.C., Rodriguez, A.A., Liu, M.C., Pohlmann, P.R., Esserman, L., Rugo, H.S., DeMichele, A., Veer, L.J. Van't
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
A novel biomarker to predict DNA-Repair-inhibitor response in stage I-III high risk breast cancer patients
Barcaru, A., Kuilman, M.M., Wolf, D., Yau, C., Choy, E.B.M., Audeh, W.M., Brown-Swigart, L., Hirst, G.L., Symmans, F.W., Liu, M.C., Nanda, R., Esserman, L.J., van ‘t Veer, L.J., Glas, A.M., Mittempergher, L.
Published in European journal of cancer (1990) (01.11.2022)
Published in European journal of cancer (1990) (01.11.2022)
Get full text
Journal Article
Abstract P3-10-14: LIV-1 expression in primary breast cancers in the I-SPY 2 TRIAL
Yau, C, Brown-Swigart, L, Asare, S, Esserman, L, van' t Veer, L, Beckwith, H, Forero, A, Rugo, H
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies
Yau, C, Wolf, DM, Campbell, M, Savas, P, Lin, S, Brown-Swigart, L, Hirst, G, Asare, S, Zhu, Z, Loi, S, DeMichele, A, Yee, D, Berry, D, Esserman, L, van 't Veer, L
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Yau, C, Wolf, D, Brown-Swigart, L, Hirst, G, Sanil, A, Singhrao, R, Asare, S, DeMichele, A, Berry, D, Esserman, L, van 't Veer, L, Nanda, R, Liu, M, Yee, D
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract P2-09-08: Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Wolf, D, Yau, C, Brown-Swigart, L, Hirst, G, Schmidt, E, Townson, S, Cristescu, R, Asare, S, Berry, D, Esserman, L, van 't Veer, L, Tripathy, D, Chien, J
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial
Campbell, M, Yau, C, Borowsky, A, Vandenberg, S, Wolf, D, Rimm, D, Nanda, R, Liu, M, Brown-Swigart, L, Hirst, G, Asare, S, van't Veer, L, Yee, D, DeMichele, A, Berry, D, Esserman, L
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract P3-10-02: Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL
Wolf, DM, Yau, C, Wulfkuhle, J, Petricoin, E, Campbell, M, Brown-Swigart, L, Hirst, G, Asare, S, Zhu, Z, Lee, EP, Delson, A, Pohlmann, P, Hylton, N, Liu, MC, Symmans, F, DeMichele, A, Yee, D, Berry, D, Esserman, L, van 't Veer, L
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract PD2-01: Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL
Magbanua, MJM, Brown-Swigart, L, Hirst, GL, Yau, C, Wolf, D, Ma, AA, Bergin, E, Venters, S, Sethi, H, Wu, H-T, Salari, R, Tin, T, Sawyer, S, Louie, M, Zimmermann, B, Lin, C-HJ, Keats, J, Liang, WS, Cuyugan, L, Enriquez, D, Tripathy, D, Chien, AJ, Forero, A, DeMichele, A, Liu, M, Delson, AL, Asare, S, Esserman, L, van't Veer, L
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Temporal dissection of p53 function in vitro and in vivo
Evan, Gerard I, Christophorou, Maria A, Martin-Zanca, Dionisio, Soucek, Laura, Lawlor, Elizabeth R, Brown-Swigart, Lamorna, Verschuren, Emmy W
Published in Nature genetics (01.07.2005)
Published in Nature genetics (01.07.2005)
Get full text
Journal Article
Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Wolf, DM, Yau, C, Sanil, A, Glas, A, Petricoin, C, Wulfkuhle, J, Brown-Swigart, L, Hirst, G, Buxton, M, DeMichele, A, Hylton, N, Symmans, F, Yee, D, Paoloni, M, Esserman, L, Berry, D, Rugo, H, Olapade, O, van 't Veer, L
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract P3-05-02: Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
Gallagher, RI, Yau, C, Wolf, DM, Dong, T, Hirst, G, Brown-Swigart, L, Buxton, M, DeMichele, A, van't Veer, L, Yee, D, Paoloni, M, Esserman, L, Berry, D, Park, J, Petricoin, EF, Wulfkuhle, JD
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract P3-07-48: Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial
Wulfkuhle, JD, Yau, C, Wolf, DM, Gallagher, RI, Deng, J, Brown-Swigart, L, Hirst, G, I-SPY 2 Trial, Investigators, Rugo, H, Olopade, OI, Esserman, L, Berry, D, van't Veer, L, Petricoin, EF
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
751 MYC Inhibition as a Therapeutic Strategy in Glioma
Annibali, D, Whitfield, J.R, Favuzzi, E, Nasi, S, Swigart, L. Brown, Evan, G.I, Soucek, L
Published in European journal of cancer (1990) (01.07.2012)
Published in European journal of cancer (1990) (01.07.2012)
Get full text
Journal Article